JP2016521685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521685A5 JP2016521685A5 JP2016515629A JP2016515629A JP2016521685A5 JP 2016521685 A5 JP2016521685 A5 JP 2016521685A5 JP 2016515629 A JP2016515629 A JP 2016515629A JP 2016515629 A JP2016515629 A JP 2016515629A JP 2016521685 A5 JP2016521685 A5 JP 2016521685A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- protein
- homology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims 16
- 102000004169 proteins and genes Human genes 0.000 claims 14
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 4
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 4
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 4
- 239000003114 blood coagulation factor Substances 0.000 claims 4
- 239000013612 plasmid Substances 0.000 claims 4
- 239000002158 endotoxin Substances 0.000 claims 3
- 229920006008 lipopolysaccharide Polymers 0.000 claims 3
- 241000607528 Aeromonas hydrophila Species 0.000 claims 2
- 241000588923 Citrobacter Species 0.000 claims 2
- 241000588697 Enterobacter cloacae Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 2
- 241000588655 Moraxella catarrhalis Species 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 241000588770 Proteus mirabilis Species 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 241000607715 Serratia marcescens Species 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000002360 preparation method Methods 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 208000037487 Endotoxemia Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310206823.5 | 2013-05-29 | ||
| CN201310206823.5A CN104211802B (zh) | 2013-05-29 | 2013-05-29 | 人凝血因子轻链蛋白及其应用 |
| PCT/CN2014/078108 WO2014190871A1 (zh) | 2013-05-29 | 2014-05-22 | 人凝血因子轻链蛋白及其应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016521685A JP2016521685A (ja) | 2016-07-25 |
| JP2016521685A5 true JP2016521685A5 (enExample) | 2017-07-06 |
| JP6441906B2 JP6441906B2 (ja) | 2018-12-19 |
Family
ID=51987992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515629A Active JP6441906B2 (ja) | 2013-05-29 | 2014-05-22 | ヒト凝固因子軽鎖タンパク質及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US9782461B2 (enExample) |
| EP (1) | EP3006461A4 (enExample) |
| JP (1) | JP6441906B2 (enExample) |
| CN (2) | CN104211802B (enExample) |
| WO (1) | WO2014190871A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111272889B (zh) * | 2020-02-10 | 2022-02-25 | 济宁学院 | 基于蛋白质组学定量技术分析嗜水气单胞菌感染日本沼虾血细胞差异表达蛋白质的方法 |
| CN116539893A (zh) * | 2023-04-23 | 2023-08-04 | 天津医科大学总医院 | 一种细胞内凝血因子ⅹ的质谱检测方法、应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5940799A (en) * | 1994-10-24 | 2000-02-17 | Novo Nordisk A/S | Modified factor VII |
| AU2002322264A1 (en) * | 2001-06-14 | 2003-01-02 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human growth factor with homology to epidermal growth factor, bgs-8, expressed highly in immune tissue |
| US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| CA2528239A1 (en) * | 2003-06-05 | 2004-12-16 | Canadian Blood Services | Mutants of the factor vii epidermal growth factor domain |
| EP1644504B8 (en) * | 2003-06-19 | 2010-06-02 | Bayer HealthCare LLC | Factor vii or viia gla domain variants |
| CN101384613A (zh) * | 2006-02-10 | 2009-03-11 | 德玛根股份公司 | 新型抗微生物肽及其应用 |
| US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| AU2011281599A1 (en) * | 2010-07-22 | 2013-03-07 | Csl Behring Gmbh | An ancestral serine protease coagulation cascade exerts a novel function in early immune defense |
| FR2972114B1 (fr) * | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| CN102875685B (zh) * | 2012-09-29 | 2013-12-25 | 郑骏年 | 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途 |
-
2013
- 2013-05-29 CN CN201310206823.5A patent/CN104211802B/zh active Active
-
2014
- 2014-05-22 WO PCT/CN2014/078108 patent/WO2014190871A1/zh not_active Ceased
- 2014-05-22 US US14/894,415 patent/US9782461B2/en active Active
- 2014-05-22 EP EP14804149.4A patent/EP3006461A4/en active Pending
- 2014-05-22 CN CN201480042517.5A patent/CN105473611B/zh active Active
- 2014-05-22 JP JP2016515629A patent/JP6441906B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sahoo et al. | Antimicrobial peptides derived from insects offer a novel therapeutic option to combat biofilm: A review | |
| Bitrus et al. | Staphylococcus aureus: A review of antimicrobial resistance mechanisms | |
| JP2016520599A5 (enExample) | ||
| Nuti et al. | Antimicrobial peptides: a promising therapeutic strategy in tackling antimicrobial resistance | |
| Van et al. | The antibiotic resistance characteristics of non-typhoidal Salmonella enterica isolated from food-producing animals, retail meat and humans in South East Asia | |
| Srey et al. | Biofilm formation in food industries: A food safety concern | |
| JP2012530509A5 (enExample) | ||
| JP2016532690A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| Sivieri et al. | Gut microbiota and antimicrobial peptides | |
| BR112012016982B8 (pt) | bactéria de ácido lático recombinante de grau alimentício e composição terapêutica | |
| WO2011110655A3 (en) | Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease | |
| GB201018518D0 (en) | Novel endolysin | |
| TW201204262A (en) | Method of reducing biofilms | |
| Sun et al. | Three novel B-type mannose-specific lectins of Cynoglossus semilaevis possess varied antibacterial activities against Gram-negative and Gram-positive bacteria | |
| WO2010123200A2 (ko) | 병원성 장내세균을 사멸시키는 박테리오파지 | |
| Cacciotto et al. | Eating the enemy: mycoplasma strategies to evade neutrophil extracellular traps (NETs) promoting bacterial nucleotides uptake and inflammatory damage | |
| JP2016515388A5 (enExample) | ||
| JP2016521685A5 (enExample) | ||
| EA201991233A1 (ru) | Новый эндолизин | |
| EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
| RU2014109402A (ru) | ПРОДУЦИРУЕМЫЙ БАКТЕРИЯМИ МИКРОЦИН С, НОВЫЙ АНТИМИКРОБНЫЙ ПЕПТИД, ЭФФЕКТИВНЫЙ ПРОТИВ ПАТОГЕННЫХ МИКРООРГАНИЗМОВ, НАПРИМЕР ЭНТЕРОГЕМОРРАГИЧЕСКОЙ Escherichia coli (EHEC) | |
| PH12014501443A1 (en) | 1,3-diphenylpropane derivatives, preparations and uses thereof | |
| Saribayeva et al. | Study antagonistic activity, the level of resistance to hydrochloric acid and bile probiotic strain Escherichia coli | |
| Zhao et al. | Expression, purification, and in vitro comparative characterization of avian beta-defensin-2,-6, and-12 |